ArticleTheranostics2017
Chelator-Free Radiolabeling of SERRS Nanoparticles for Whole-Body PET and Intraoperative Raman Imaging.
Article in Theranostics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Raman and surface-enhanced Raman spectroscopy for intraoperative cancer diagnostics: sentinel lymph node biopsy, biomarkers and translational challenges.Frontiers in bioengineering and biotechnology · 2026Review
- Nanoparticle Detection in Biology and Medicine: A Review.Biosensors · 2025Review
- Self-stacked small molecules for ultrasensitive, substrate-free Raman imaging in vivo.Nature biotechnology · 2025Article
- Precision Oncology: Advances in Drug Delivery and Imaging.Recent advances in drug delivery and formulation · 2025Review
- Nanoparticle-Based Approaches in the Diagnosis and Treatment of Brain Tumors.Journal of clinical medicine · 2024Review
- Plasmonic nanoparticle sensors: current progress, challenges, and future prospects.Nanoscale horizons · 2024Review
- Exploring innovative strides in radiolabeled nanoparticle progress for multimodality cancer imaging and theranostic applications.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Review
- The Emerging Role of Raman Spectroscopy as an Omics Approach for Metabolic Profiling and Biomarker Detection toward Precision Medicine.Chemical reviews · 2023Review
- Design and Synthesis of SERS Materials for In Vivo Molecular Imaging and Biosensing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Radiolabeled nanomaterial for cancer diagnostics and therapeutics: principles and concepts.Cancer nanotechnology · 2023Review
- Non-Invasive and Real-Time Monitoring of the Breast Cancer Metastasis Degree via Metabolomics.Cancers · 2022Article
- Nanotheranostics for Image-Guided Cancer Treatment.Pharmaceutics · 2022Review
- Biomedical Applications of Iron Oxide Nanoparticles: Current Insights Progress and Perspectives.Pharmaceutics · 2022Review
- Advances in Surface Enhanced Raman Spectroscopy forNanotheranostics · 2022Review
- Design and synthesis of gold nanostars-based SERS nanotags for bioimaging applications.Nanotheranostics · 2022Review
- Visualizing surface marker expression and intratumoral heterogeneity with SERRS-NPs imaging.Nanotheranostics · 2022Article
- Advances in Development of Radiometal Labeled Amino Acid-Based Compounds for Cancer Imaging and Diagnostics.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Silica-Based Nanoframeworks Involved Hepatocellular Carcinoma Theranostic.Frontiers in bioengineering and biotechnology · 2021Review
- A review of advances in the last decade on targeted cancer therapy usingAmerican journal of nuclear medicine and molecular imaging · 2021Review
- Image-guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
A single contrast agent that offers whole-body non-invasive imaging along with the superior sensitivity and spatial resolution of surface-enhanced resonance Raman scattering (SERRS) imaging would allow both pre-operative mapping and intraoperative imaging and thus be highly desirable. We hypothesized that labeling our recently reported ultrabright SERRS nanoparticles with a suitable radiotracer would enable pre-operative identification of regions of interest with whole body imaging that can be rapidly corroborated with a Raman imaging device or handheld Raman scanner in order to provide high precision guidance during surgical procedures. Here we present a straightforward new method that produces radiolabeled SERRS nanoparticles for combined positron emission tomography (PET)-SERRS tumor imaging without requiring the attachment of molecular chelators. We demonstrate the utility of these PET-SERRS nanoparticles in several proof-of-concept studies including lymph node (LN) tracking, intraoperative guidance for LN resection, and cancer imaging after intravenous injection. We anticipate that the radiolabeling method presented herein can be applied generally to nanoparticle substrates of various materials by first coating them with a silica shell and then applying the chelator-free protocol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.